Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.49 |
| ▸ | HTR1D | P28221 | 1/20 | 0.49 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5764552 | 1.00 | KDM4E (0.51) | KDM4EALDH1A1CHRM4HTR1DOPRL1 | |
| Hydrochloric Acid SCHEMBL7091076 | 0.92 | HRH3 (0.46) | KDM4EALDH1A1CHRM4HTR1DHRH3 | |
| SCHEMBL6200425 | 0.91 | KDM4E (0.53) | KDM4EALDH1A1CHRM4OPRL1ACHE | |
| Hydrochloric Acid SCHEMBL6495382 | 0.86 | HTR1D (0.53) | KDM4EALDH1A1CHRM4HTR1DOPRL1 | |
| Hydrochloric Acid SCHEMBL6495374 | 0.86 | HTR1D (0.53) | KDM4EALDH1A1CHRM4HTR1DOPRL1 | |
| Hydrochloric Acid SCHEMBL5765402 | 0.86 | HTR1D (0.53) | KDM4EALDH1A1CHRM4HTR1DOPRL1 | |
| Hydrochloric Acid SCHEMBL5765407 | 0.86 | HTR1D (0.53) | KDM4EALDH1A1CHRM4HTR1DOPRL1 | |
| SCHEMBL6746046 | 0.85 | KDM4E (0.60) | KDM4EALDH1A1OPRL1OPRM1 | |
| SCHEMBL23778401 | 0.80 | HSD11B1 (0.47) | OPRL1HRH3 | |
| SCHEMBL10567213 | 0.78 | OPRM1 (0.53) | KDM4EALDH1A1OPRL1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1286967-B1 | CYCLOHEXANE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME (GB) | 2006-09-27 | — | — | EP | disclosed |
| US-7105507-B2 | Cyclohexane derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LIMITED (GB) | 2006-09-12 | — | — | US | disclosed |
| US-20030236250-A1 | Cyclohexane derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LTD. (GB) | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236250-A1 | Cyclohexane derivatives and their use as therapeutic agents | CNR2, CNR1, HTR1A | KDM4E 1695/4885ALDH1A1 1452/4885CHRM4 1348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.